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Abstract Congenital heart disease (CHD) affects 0.8%
of live births and over the past decades technical
improvements and large-scale repair has led to in-
creased survival into adulthood of over 95% of the
new-born. A new group of patients, those who sur-
vived their congenital heart defect, has emerged but
late complications including heart failure, pulmonary
hypertension (PH), arrhythmias, aneurysms and en-
docarditis appeared numerous, with a huge impact on
mortality and morbidity. However, innovations over
the past years have changed the landscape of adult
CHD dramatically. In the diagnostic process impor-
tant improvements have been made in the use of MRI,
biomarkers, e-health concepts and 3D visualisation
of anatomy. Care is now concentrated in specialised
centres, with a continuous emphasis on education
and the introduction of weekly multidisciplinary con-
sultations on diagnosis and intervention. Surgery
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and percutaneous intervention have been refined and
new concepts applied, further reducing the burden
of the congenital malformations. Research has ma-
tured from case series to global networks. Currently,
adults with CHD are still facing high risks of early
mortality and morbidity. By global collaboration and
continuous education and development and innova-
tion of our diagnostic and therapeutic arsenal, we will
improve the perspectives of these young patients.
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Introduction
Birth prevalence of congenital heart disease (CHD) is
estimated to be 8 cases per 1000 live births and up to
95% survive until adulthood (Fig. 1; [1]). A decline is
to be expected as nowadays up to one third of the de-
fects and 57% to 85% of all severe lesions are detected
before the end of the pregnancy, next to prevention
by the prescription of vitamin supplements.
Fig. 1 Uncertainty of clinical course of adults with congenital
heart disease
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Fig. 2 Estimated survival from the age of 18 of adults with
congenital heart disease stratified for disease severity
Data from the Dutch National CONCOR registry
show that survival of adults with lesions of moderate
and severe complexity (Fig. 2) is limited compared
with the general population and two thirds of the
patients die from a cardiac cause (Fig. 3); [2]). Sex
differences are common in adult congenital heart
disease (ACHD) [3]. Male CHD patients also have
a greater risk of endocarditis, aortic events, and indi-
cations for internal cardiac defibrillator implantation,
while women tend to be more at risk of pulmonary
hypertension (PH). The 30-day in-hospital surgical
mortality for CHD appeared to be higher in young
men than in women [4]. It has been demonstrated
that adult men with an atrial septal defect type 2 have
a worse survival compared with females [5].
Over the past decades, awareness has grown about
the need to deliver appropriate care in patients with
end-stage CHD [6]. There are several important end-
of-life issues, such as how to cope with a poor prog-
nosis when, early in life, a complete repair and nor-
mal lifespan was expected. Crucial components in
the end-of-life process should be discussed during the
clinical course, e.g. switching off the ICD and appoint-
ing a family member as a healthcare representative.
Diagnostics
Next to echocardiography (3D and strain) and com-
puted tomography (low radiation and high resolu-
tion), MRI has emerged over the past few decades
as the superior imaging modality for complex ACHD
patients. Rapid, high-resolution imaging of complex
anatomy and accurate quantitative assessment of
physiology and function have become possible [7].
Fig. 3 Causes of death of adults with congenital heart dis-
ease
New techniques, including flow quantification, 3D
angiography, perfusion imaging and assessment of
myocardial viability have become available. Nowa-
days, our understanding of pathophysiology has in-
creased, for example insight into flow patterns, wall
shear stress and energy loss in several clinical condi-
tions such as bicuspid aortic valve, post-coarctectomy
haemodynamics and the Fontan circulation.
Upcoming techniques are 3D printing, in which
computed tomography or MRI data may be used to
reconstruct the heart and vessels [8]. Another promis-
ing technique is computer-generated real-time digital
holography. Because current 3D images are displaced
as a single plane on a 2D screen, it precludes direct
interaction and hampers the perception of depth and
spatial relationships [9]. These models can be used
to precisely visualise complex anatomy, plan surgical
procedures, and teach trainees and patients.
Biomarkers are becoming increasingly used in
ACHD as clinicians start to recognise the diagnostic
and prognostic significance. Brain natriuretic peptide,
a cardiac hormone secreted by cardiac myocytes, re-
sponds to ventricular wall stress secondary to volume
and pressure overload and is elevated in most adults
with complex CHD [10]. Troponin, biomarkers of
myocardial damage and soluble suppression of tu-
Dutch contribution to the field
 Excellent care for adult patients with congenital
heart disease.
 Establishment of a national registry and DNA
bank (CONCOR).
 Important contribution in scientific research in
adult congenital heart disease.
 Leading role in global research networks.
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morgenicity 2, a biomarker of myocardial fibrosis,
have prognostic value in ACHD patients with chronic
heart failure (HF) and PH. Although the precise posi-
tion of biomarkers still needs to be determined, they
are increasingly being incorporated in daily clinical
practice for risk stratification and guidance of therapy.
E-health is an upcoming modality with high po-
tential. E-health is a concept covering several pro-
cesses from telemedicine, teleradiology, teleconsult-
ing, monitoring vital signs, to educational websites.
The greatest impact seems to be in the early diagno-
sis of complications. In ACHD patients it has been
shown that e-health is feasible with high adherence
enabling early detection of arrhythmias, hypertension
and HF. This may lead to a swift therapeutic response
or remote reassurance in case of normal findings [11].
Late complications
The outstanding improvements in surgical and inter-
ventional techniques over the last decades have re-
sulted in a substantial decrease in mortality and mor-
bidity of the ACHD population. This result has evolved
from a strategy of not only restoring anatomy, func-
tion or haemodynamics, but also from preventing and
solving long-term complications. Most complications
are related to valvular dysfunction and fibrosis as a re-
sult of longstanding volume or pressure overload and
the intervention itself, while endocarditis remains rel-
evant. Complications of the modern Western lifestyle
such as atherosclerosis, diabetes and obesity need to
be taken into account as well.
HF phenotypes in ACHD can be categorised into
those with uncorrected defects, a repaired or palli-
ated status and a failing single ventricle physiology
[12]. While in acquired HF a broad arsenal of evi-
dence-based medical therapy is available, clinical ev-
idence on left and especially right ventricular failure
in ACHD is sparse. In end-stage HF, there is limited
experience with mechanical support and transplanta-
tion. Restricting factors may be anatomy, presence of
PH or immunological factors due to multiple transfu-
sions during previous surgery [12].
Arrhythmogenesis is induced by a myriad of vari-
ables including anatomical defects, surgical scarring,
hypoxaemia, haemodynamic sequelae and genetic
factors [13]. Any new-onset or worsening of arrhyth-
mia should be of concern and prompts haemody-
namic assessment [14]. The interaction between
ACHD and electrophysiology has resulted in a steep
increase of introduction of mapping techniques, ab-
lation and device therapies in ACHD.
Despite medical advances, the prevalence of endo-
carditis did not decrease [15]. Although the number
of cyanotic patients has reduced, more and more pa-
tients receive prosthetic materials, where especially
percutaneous pulmonary valve prostheses are associ-
ated with increased endocarditis risks [16].
ACHD patients are not exempt from acquired car-
diovascular diseases. Compared with the general pop-
ulation, the relative risk for developing coronary artery
disease (CAD) is between 4.6 and 12.0 for men and
women aged 20 years, respectively [17]. Not only the
presence of CAD, but also comorbidity such as dia-
betes, obesity and renal impairment, now play a role
in timing and decision-making in ACHD.
Pulmonary hypertension
PH is a relatively common complication in CHD as ap-
proximately 4–10% will develop PH with an incidence
of 35% in the elderly [18]. It significantly affects mor-
tality; for example, in Eisenmenger syndrome mortal-
ity is severely impaired and morbidity limits exercise
capacity and decreases quality of life [19, 20].
Prevention of pulmonary arterial hypertension
(PAH) is of paramount importance. Significant shunts
should be closed with surgical or transcatheter repair
shortly after diagnosis. Follow-up of closed defects is
obligatory to detect PAH in an early phase.
Treatment of PAH in CHD should be a multidis-
ciplinary team approach and individualised for each
patient according to the underlying aetiology, haemo-
dynamics and clinical status. Supportive therapy is
mainly given to avoid or treat complications related
to PH-CHD and includes diuretics to unload the right
ventricle, oxygen administration, psychosocial sup-
port, and supervised rehabilitation.
In the last decades, several drugs interfering with
one of the three pathways leading to pulmonary vas-
cular remodelling have become available. In the past,
endothelin receptor antagonists, e.g. bosentan, have
shown favourable outcome in exercise capacity and
pulmonary haemodynamics in patients with Eisen-
menger syndrome [21]. However, in a recent ran-
domised study in Eisenmenger patients, macitentan
did not show superiority over placebo on improve-
ment in the six-minute walk distance [22]. Interest-
ingly, in a large placebo controlled study, macitentan
significantly reduced the composite endpoint of mor-
bidity and mortality in PAH, including CHD [23].
Secondly, phosphodiesterase type 5 inhibitors, such
as sildenafil, and guanylate cyclase stimulators, both
result in vasodilatation of the pulmonary vasculature
and are approved for the treatment of PAH. Recently,
in a post-hoc analysis in the subgroup of CHD-PAH
patients, an oral selective prostacyclin receptor ago-
nist selexipag showed a delay in disease progression
[24]. Nowadays, upfront combination therapy with
at least two different PH-specific drugs has become
standard when initiating PAH-specific therapy and
treatment should include a goal-oriented approach.
In patients who are highly symptomatic (functional
class IV) intravenous epoprostenol showed favourable
effects on exercise capacity, although central lines in-
crease the risk of paradoxical embolism and sepsis in
patients with Eisenmenger syndrome [25].
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Fig. 4 Developments over the years in cardiac surgery and
interventional cardiology. MRI magnetic resonance imaging,
TAVI transcatheter aortic valve implantation, PDA patent duc-
tus arteriosus, PA pulmonary artery, AV aortic valve, PV pul-
monary valve, VSD ventricular septal defect, ASD atrial sep-
tal defect, Pears Personalized External Aortic Root Support,
Tx cardiac transplantation, HLTx heart-lung transplantation,
AVSD atrioventricular septal defect, TAPVD Total anomalous
pulmonary venous drainage, CPB cardiac pulmonary bypass,
TOF tetralogy of Fallot, BT Blalock-Taussig
Percutaneous interventions
In the last decade, development of percutaneous tech-
niques has significantly contributed to the manage-
ment of patients with ACHD (Fig. 4; [26]), Tradition-
ally, simple percutaneous device closure of atrial sep-
tal defects type 2 in children and adults have been the
treatment of choice over surgery (when feasible re-
garding anatomy; size, aortic rim). It is expected that
the number of patients treated for closure of patent
foramen ovale (PFO) for cryptogenic stroke will in-
crease after recent meta-analyses of randomised trials
showed significant clinical benefit [27]. Percutaneous
balloon valvuloplasty for congenital pulmonary and
aortic stenosis have shown reliable and long-lasting
results. Device closure of patent ductus arteriosus in
children and adults has long been common practice
and is recommended as first-choice method of closure
if technically feasible.
Percutaneous treatment of native coarctation and
re-coarctation in adolescents and adults with stents
is the first choice in many centres. Upper limb hy-
pertension and a pressure gradient >20mmHg or
a stenosis >50% on imaging are the criteria for inter-
vention. Stent placement for pulmonary artery steno-
sis, as stand-alone procedure or as hybrid procedure
with direct visual stent placement during surgical
pulmonary valve replacement, is feasible and shows
good results [28]. Transcatheter valve implantation for
pulmonary valve regurgitation or stenosis in patients
with pulmonary conduits (after surgical treatment for
Tetralogy of Fallot or Ross procedures) has signifi-
cantly changed the outlook for these patients. Life-
time strategies with alternating surgical and percu-
taneous valve implantation (and valve-in-valve) have
emerged, with both the Melody valve (Medtronic) and
Edwards valve (Edwards lifesciences) showing excel-
lent and lasting results [29]. Valve endocarditis after
percutaneous implantation remains a concern [30].
Timing of pulmonary valve replacement in asymp-
tomatic patients with signs of right ventricular en-
largement, reduced ejection fraction or arrhythmias
remains challenging and requires a multidisciplinary
approach in dedicated, highly specialised centres.
Future perspectives include the development of
bioresorbable devices for ASD/PFO closure [31]. In
addition, quality standards and volume requirements
will be established for centres that provide care for
adults with CHD [32]. These will include formal train-
ing for adult interventional cardiologists in ACHD
interventions, close collaboration with paediatric
cardiologists (joint intervention teams), surgeons,
imaging cardiologists, electrophysiologists and multi-
disciplinary decision-making (Grown-Up Congenital
Heart disease/GUCH heart team). Interaction with in-
terventional cardiologists involved in structural heart
disease will enhance skills and options for ACHD
interventions. Techniques from transcatheter aortic
valve implantation (TAVI) programs and the applica-
tion ofmitraclips for mitral and tricuspid regurgitation
will be translated to use in ACHD patients, as will new
percutaneous valves, annuloplasty devices, plugs for
paravalvular leak closure etc.
Cardiac surgery
Personalised external aortic root support (PEARS) is
a low-risk surgical procedure to strengthen the aortic
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root in connective tissue disorders such as Marfan’s
syndrome and probably also degenerative disorders
(Fig. 4; [33]). Long-term results are promising, albeit
that the number of procedures is limited. Interest-
ingly, this PEARS support also seems to work well in
the Ross procedure, where the variable dilatation of
the pulmonary autograft under aortic pressures can
be prevented by the same support.
Valve sparing root replacement has added consid-
erably to the decrease in long-term morbidity of pa-
tients with congenital aortic valve pathology [34]. The
longevity of this repair not only depends on the tech-
nique, but also on the skills of the surgeon as the
pathology is very variable. Because these patients are
often young, repeat procedures must be anticipated.
This calls for workshops to educate surgeons in this
rather artful procedure.
Interestingly, all varieties of prosthetic valves de-
signed for the aortic valve perform worse in the
pulmonary position [35]. Homografts for pulmonary
valve disease have proven to have the absolute best
prognosis, the paucity of their availability being cur-
rently the major drawback. As late pulmonary valve
replacement by transcatheter valves has shown to
be associated with continuing risk of endocarditis
of 1–3% per year, surgical solutions associated with
a minimum of long-term morbidity are of continued
interest [30]. We should strive for a pulmonary valve
prosthesis specifically designed for that very position
[36].
Late Fontan failure including the elevated central
venous pressure is mostly caused by increasing pul-
monary resistance due to the un-physiological non-
pulsatile flow. Nonetheless, the solution has proven
to be cardiac transplantation, after which pulmonary
re-remodelling may well occur. A few cases have been
described with promising results with cardiac trans-
plantation, also unusual vascular anatomical situa-
tions call for lowering the threshold for transplanta-
tion [37]. These referrals should also be prompted
by hepatic disorders preceding prohibitive cirrhosis
or malignancy due to abdominal congestion caused
by the chronic low output and high central venous
pressure state.
Clinical research
Research on ACHD has changed dramatically dur-
ing the past decades from case series and retro-
spective studies to international prospective cohorts
and randomised controlled clinical trials, and from
chromosomal studies to whole-genome sequencing.
Our national registry (CONCOR) and international
networks such as the ISACHD and the EuroGUCH
facilitate worldwide collaborative ACHD research and
education. Several international initiatives have been
undertaken to improve efficacy, such as the NOTE
Registry, a global study assessing the efficacy and
safety of non-vitamin K oral antagonists in prevent-
ing thromboembolic complications in ACHD and the
ROPAC study, describing the outcome of pregnancy
in cardiac patients, including ACHD [38, 39]. Much
of this research is integrated in the 2020 European
Cardiac Society guideline on adult CHD. Moreover,
the several clinical recommendations on staff and
institutional requirements to run an ACHD program
have been published [40]. Due to these initiatives,
specialised medical care was increasingly delivered
to adult patients with CHD, resulting in a dramatic
increase of referral to the specialised ACHD centres
and a significant reduction in mortality and morbidity
in patients with ACHD.
Conclusion
In the past decades tremendous progress has been
made in ACHD care. However, we are facing new chal-
lenges to further reduce early mortality andmorbidity.
By applying improvements in diagnostics and innova-
tions in our therapeutic arsenal together with global
collaboration and education, our ACHD patients may
benefit from these future achievements.
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